JP2015526074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526074A5 JP2015526074A5 JP2015524417A JP2015524417A JP2015526074A5 JP 2015526074 A5 JP2015526074 A5 JP 2015526074A5 JP 2015524417 A JP2015524417 A JP 2015524417A JP 2015524417 A JP2015524417 A JP 2015524417A JP 2015526074 A5 JP2015526074 A5 JP 2015526074A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- subject
- jak
- cish
- socs2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 59
- 230000014509 gene expression Effects 0.000 claims description 39
- 239000003112 inhibitor Substances 0.000 claims description 36
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 32
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 32
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 32
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims description 26
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 claims description 26
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims description 26
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 26
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 claims description 26
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims description 24
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 24
- 102100027641 DNA-binding protein inhibitor ID-1 Human genes 0.000 claims description 20
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 18
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 16
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 16
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- -1 EPOR Proteins 0.000 claims description 9
- 206010066476 Haematological malignancy Diseases 0.000 claims description 9
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 8
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 8
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical group C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 238000011287 therapeutic dose Methods 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- BLLAEKRDPJDWAJ-OAHLLOKOSA-N 4-[1-[(1R)-1-cyclopentylpropyl]pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidine Chemical group N1=CN=C(C2=C1NC=C2)C=1C=NN(C=1)[C@H](CC)C1CCCC1 BLLAEKRDPJDWAJ-OAHLLOKOSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 201000007925 mature T-cell and NK-cell lymphoma Diseases 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676484P | 2012-07-27 | 2012-07-27 | |
| US61/676,484 | 2012-07-27 | ||
| US201361769271P | 2013-02-26 | 2013-02-26 | |
| US61/769,271 | 2013-02-26 | ||
| US201361829327P | 2013-05-31 | 2013-05-31 | |
| US61/829,327 | 2013-05-31 | ||
| PCT/US2013/051824 WO2014018632A1 (en) | 2012-07-27 | 2013-07-24 | Prediction of treatment response to jak/stat inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526074A JP2015526074A (ja) | 2015-09-10 |
| JP2015526074A5 true JP2015526074A5 (cg-RX-API-DMAC7.html) | 2016-09-08 |
Family
ID=48906529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524417A Pending JP2015526074A (ja) | 2012-07-27 | 2013-07-24 | Ｊａｋ／ｓｔａｔ阻害剤に対する治療反応の予測 |
Country Status (18)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| CR20170410A (es) | 2015-03-10 | 2017-11-08 | Aduro Biotech Inc | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen interferon" |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN106544414A (zh) * | 2016-10-09 | 2017-03-29 | 广州泰诺迪生物科技有限公司 | 一种检测肺癌脑转移样本中stat3和lck的方法 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107137701B (zh) * | 2017-05-07 | 2020-07-14 | 山东兴瑞生物科技有限公司 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US20060194275A1 (en) * | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
| WO2010048123A2 (en) * | 2008-10-20 | 2010-04-29 | Eckhardt S Gail | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| NZ597140A (en) * | 2009-06-05 | 2014-01-31 | Cephalon Inc | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| BR112013013684A2 (pt) * | 2010-12-03 | 2016-09-06 | Ym Biosciences Australia Pty | tratamento das condiçóes mediadas por jak-2 |
-
2013
- 2013-07-24 BR BR112015001521A patent/BR112015001521A2/pt not_active IP Right Cessation
- 2013-07-24 EP EP13742819.9A patent/EP2877596A1/en not_active Withdrawn
- 2013-07-24 AU AU2013295855A patent/AU2013295855A1/en not_active Abandoned
- 2013-07-24 JP JP2015524417A patent/JP2015526074A/ja active Pending
- 2013-07-24 SG SG11201500261VA patent/SG11201500261VA/en unknown
- 2013-07-24 RU RU2015106714A patent/RU2015106714A/ru not_active Application Discontinuation
- 2013-07-24 HK HK15105427.5A patent/HK1205198A1/xx unknown
- 2013-07-24 CN CN201380040005.0A patent/CN104508149A/zh active Pending
- 2013-07-24 US US14/417,632 patent/US20150299796A1/en not_active Abandoned
- 2013-07-24 WO PCT/US2013/051824 patent/WO2014018632A1/en not_active Ceased
- 2013-07-24 CA CA2880198A patent/CA2880198A1/en not_active Abandoned
- 2013-07-24 KR KR20157004583A patent/KR20150038241A/ko not_active Withdrawn
- 2013-07-24 MX MX2015001269A patent/MX2015001269A/es unknown
- 2013-07-26 TW TW102126993A patent/TW201409030A/zh unknown
-
2015
- 2015-01-16 TN TNP2015000019A patent/TN2015000019A1/fr unknown
- 2015-01-22 IL IL236897A patent/IL236897A0/en unknown
- 2015-01-26 CL CL2015000192A patent/CL2015000192A1/es unknown
- 2015-01-26 PH PH12015500169A patent/PH12015500169A1/en unknown
-
2017
- 2017-07-14 AU AU2017204894A patent/AU2017204894A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526074A5 (cg-RX-API-DMAC7.html) | ||
| Arbour et al. | Treatment outcomes and clinical characteristics of patients with KRAS-G12C–mutant non–small cell lung cancer | |
| Wagle et al. | A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types | |
| Choueiri et al. | Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial | |
| Buder et al. | The potential of liquid biopsies | |
| Tsukioka et al. | Sarcopenia is a novel poor prognostic factor in male patients with pathological Stage I non-small cell lung cancer | |
| Hughes et al. | Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase | |
| Lara et al. | Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis | |
| Nguyen et al. | Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma | |
| Kim et al. | Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing | |
| You et al. | CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: An exploratory analysis from the VELIA/GOG-3005 study | |
| JP2016500110A5 (cg-RX-API-DMAC7.html) | ||
| Chien et al. | Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling | |
| Long et al. | Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression | |
| Wyce et al. | MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers | |
| RU2015106714A (ru) | Прогнозирование ответа на лечение ингибитором jak/stat | |
| Shen et al. | LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer | |
| Wang et al. | MicroRNA-10b is upregulated and has an invasive role in colorectal cancer through enhanced Rhoc expression | |
| Zanoni et al. | Upregulated serum miR‐128‐3p in progressive and relapse‐free multiple sclerosis patients | |
| Fu et al. | Long Noncoding RNAZEB1-AS1 Expression Predicts Progression and Poor Prognosis of Colorectal Cancer | |
| Breunig et al. | BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma | |
| Olmez et al. | Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib | |
| Elhousiny et al. | Identification of inflammatory mediators associated with metastasis of oral squamous cell carcinoma in experimental and clinical studies: systematic review | |
| Hassan-Zahraee et al. | Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis | |
| Zhang et al. | An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma |